IBC Grows in Scope, Reach and Diversity
IBC2018 has closed its doors for this year and has delivered another great event with visitor figures of 55,884. As well as providing a host of new initiatives this year, the exhibition grew by 667m2 and conference delegates were up by 14% year on year. One of the most important growth figures lies in the diversity of its content with a targeted effort increasing women speakers at the conference up from 14% to 37%.
The IBC International Honour for Excellence saw its first-ever woman recipient this year, too. Joan Ganz Cooney was the co-creator of the global phenomenon that is Sesame Street, 50 years ago and her trophy was collected on her behalf by one of the street’s longest residents, Ernie.
The IBC App has provided real networking opportunities, with more than 91,000 interactions on the matchmaking platform. In addition, IBC trended number one on Twitter in the Netherlands on several days of the convention, with 185 million potential impressions and over 250,000 video views. Engagement with IBC has also increased on a year-round basis with IBC365 – the site now has over 55,000 subscribers averaging 49,000 active users per month.
Michael Crimp, IBC’s CEO, comments; “The show is about engagement, engagement, engagement. The stats are up in almost all areas and re-bookings are ahead of last year. IBC is much more than a trade show, we have developed a basket of data-driven statistics including sales leads generated on stands, conference attendance and IBC365 views and this sharing of information is pivotal to the longevity of IBC’s success and sits at the core of the organisation.”
“All of the initiatives this year have been aimed at bringing together the best minds, the original thinkers, to network and share their knowledge. As all communication becomes video and audio, IBC continues to be the place to debate the future of media, technology and entertainment,” adds Crimp.
Guiding the renewed focus this year was a new content steering group, drawn from across the industry, and chaired by Keith Underwood, Chief Operating Officer at Channel 4 in the UK.
IBC head of content Jaisica Lapsiwala, said, “This year, we have worked closely with the industry to create a programme that is not only reflective of the changes in the ecosystem, but which also paves a path forward for our industry. This has resulted in an engaging and diverse 2018 edition of IBC. An example of this was our Global Gamechangers day which brought creative, technology and business chiefs such as Zahra Rasool from Al Jazeera, Peter Salmon from Endemol and Lindsay Pattison from WPP to the stage. Threaded through the programme were the cutting-edge technologies transforming the industry. Blockchain is a great example, with a keynote from Kim Jackson of Singular DTV and papers from people who are already implementing it, like Éric Minoli of Groupe Média TFO.”
Alongside the conference, IBC hosted three invitation-only executive forums. The Leaders’ Forum looked to the future, considering what the new ecosystem could be following consolidation, acquisition and collaboration. The Cyber Security Forum considered not just the threats but how to respond to them. New to the programme this year was the Telco and Media Innovation Forum, a vital point of debate as the boundaries between media and communication blur.
Once again, IBC was the venue for an examination of the intersection of craft and technology in The Big Screen. Sessions included an in-depth look at the effects in Game of Thrones and Pixar’s Dominic Glynn talking about the animation marvel that is The Incredibles 2 – and how things have changed in the 14 years since the original movie.
The Future Zone is always a busy part of IBC, with presentations from researchers and academic bodies developing the ideas which may become the hit products five years from now. This year saw the addition of a theatre stage, presented by one of IBC’s owners, IABM, with a rolling programme of presentations discussing the ideas in more detail.
As well as the IBC Big Screen, the IABM Future Trends Theatre and the Content Everywhere Hub, staged presentations and enlarged on-stand meeting areas are becoming an increasingly common feature of exhibition stands throughout the show. “As the industry has moved on from big boxes handling discrete functions towards a software-based world that looks across the content supply chain, so the way vendors present themselves and interact with visitors at IBC has changed,” said Roger Thornton, chair of the IBC exhibition committee.
“Today, it’s all about collaboration to deliver solutions that give broadcast and media companies the agility and flexibility they need to keep ahead in this rapidly transforming media landscape. That’s why we’re seeing more and more companies using big-picture theatre presentations on their stands and providing large meeting areas where the conversations that kick off the collaboration get started.”
IBC2019 starts with the first day of conference sessions on Thursday 12 September, running until the exhibition closes on Tuesday 17 September.
Notes to Editors:
IBC is the world’s most influential media, entertainment and technology show, attracting 55,000+ attendees from more than 170 countries and combining a highly respected and peer-reviewed conference with an exhibition that showcases 1,700+ leading industry suppliers of state-of-the-art technology. In addition to the world-class exhibition and conference, IBC also encompasses the IBC Daily, IBCTV and IBC365.
IBC365 provides year-round insight and opinion into the hot topics and key trends from leading industry journalists, along with insightful whitepapers, peer reviewed technical papers, highly engaging webinars and an expansive video library.
|Conference:||12 - 16 September 2019|
|Exhibition:||13 - 17 September 2019|
For more information about IBC2019 visit: show.ibc.org/
T: +44 7718 985 252
Om Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Følg saker fra Business Wire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Business Wire
Incyte Announces Positive Interim Data from Phase 2 Trial of Pemigatinib, Its Selective FGFR Inhibitor, in Patients with Cholangiocarcinoma21.10.2018 10:45 | Pressemelding
Incyte Corporation (Nasdaq:INCY) announces updated data from its ongoing Phase 2 FIGHT-202 trial evaluating pemigatinib (INCB54828), its selective fibroblast growth factor receptor (FGFR) inhibitor, in patients with advanced/metastatic or surgically unresectable cholangiocarcinoma (bile duct cancer) who failed at least one previous treatment. In patients with FGFR2 translocations who were followed for at least eight months, interim study results demonstrated an overall response rate (ORR) of 40 percent, the primary endpoint, and a median progression free survival (PFS) of 9.2 months, a key secondary endpoint. These results are being presented at the European Society for Medical Oncology (ESMO) 2018 Congress in Munich, Germany in a poster presentation on Sunday, October 21 from 12:45 p.m. CEST to 1:45 p.m. CEST (6:45 a.m. ET to 7:45 a.m. ET). (Location: Hall A3 – Poster Area Networking Hub; Abstract #756P) “We are pleased to share updated interim results from our ongoing FIGHT-202 trial
Servier and Taiho Oncology Announce Phase III LONSURF® Study Has Met Primary and Secondary Endpoints Demonstrating Prolonged Overall Survival and Progression-Free Survival in Patients with Refractory Metastatic Gastric Cancer21.10.2018 09:10 | Pressemelding
Servier and Taiho Oncology, Inc. (U.S.), a subsidiary of Taiho Pharmaceutical Co., Ltd. (Japan), jointly announced today clinical data from the pivotal Phase III TAS-102 Gastric Study (TAGS) evaluating LONSURF® (trifluridine/tipiracil, TAS-102) versus placebo and best supportive care in patients with heavily pre-treated metastatic gastric cancer who have progressed or are intolerant to previous lines of therapy. The study met its primary endpoint of prolonged overall survival (OS) and secondary endpoint measures of progression-free survival (PFS) consistently supported the OS results, as well as continuing to demonstrate the predictable safety and tolerability profile of trifluridine/tipiracil. Data from TAGS was presented by Dr. Hendrik-Tobias Arkenau, Executive Medical Director of the Sarah Cannon Research Institute UK and an investigator for TAGS, at the ESMO 2018 Congress in Munich, Germany during an oral session (Abstract #LBA25). The study results were simultaneously published in
Phase 3 Data on Filgotinib in Biologic-Experienced Rheumatoid Arthritis to Be Presented at 2018 ACR/ARHP Annual Meeting20.10.2018 22:30 | Pressemelding
Gilead Sciences, Inc. (Nasdaq: GILD) and Galapagos NV (Euronext & NASDAQ: GLPG) today announced detailed results from the Phase 3 FINCH 2 clinical trial of filgotinib, an investigational, selective JAK1 inhibitor, in adults with moderately-to-severely active rheumatoid arthritis and prior inadequate response or intolerance to biologic agents. The data, which are being presented as a late-breaking poster at the 2018 American College of Rheumatology/Association of Rheumatology Health Professionals (ACR/ARHP) Annual Meeting in Chicago, suggest filgotinib has a potential role in addressing important unmet needs in the treatment of rheumatoid arthritis. Positive efficacy data from FINCH 2 were previously announced in September 2018. The data show statistically significant improvements in the proportion of patients achieving a range of clinical efficacy endpoints, including the proportion of patients achieving American College of Rheumatology 20 percent (ACR20, primary endpoint), 50 percent
Manchester United and True Religion Launch Denim Range19.10.2018 17:37 | Pressemelding
Manchester United (NYSE:MANU) and luxury denim brand True Religion have collaborated to launch a range of premium club branded denim wear. A first for the club, the new global partnership with the iconic American denim brand will see a range of men’s & women’s co-branded styles go on sale beginning 26th October in the club’s Megastore as well as online via United Direct and truereligion.com & eu.truereligion.com. The exclusive collection features jeans, shirts and jackets, including a highly desirable limited edition denim jacket embroidered with the club’s crest. Fans will have the opportunity to win a selection of clothing from the new range by visiting www.manutd.com/truereligion. Manchester United’s Group Managing Director, Richard Arnold, comments: “True Religion is a well-known, established name in fashion, creating unique designs without compromising on quality. The range we have collaborated on includes the same attention to detail and craftsmanship that has made True Religion
Arch Insurance Announces Strategic Leadership Changes19.10.2018 13:10 | Pressemelding
Arch Insurance today announced that Matt Shulman will assume the newly created role of CEO, Arch Insurance North America, effective January 1, 2019. In this role, he will lead Arch Insurance’s operations in the United States and Canada. He will report to Nicolas Papadopoulo, Chairman and CEO of Arch Worldwide Insurance Group. Mr. Shulman, who has more than 20 years of experience in the insurance industry, has been with Arch Insurance since 2009 and has served as the President and CEO of Arch Insurance Europe since 2016. “Matt brings significant U.S. and international experience to this role. Under his leadership, together with our senior team, Arch Insurance will continue to enhance our value proposition to our customers through a robust, diversified product portfolio, creative solutions and excellent service,” Mr. Papadopoulo said. Arch Insurance has also created a new organizational structure with three Chief Underwriting Officers (CUO) dedicated to specific lines of business. These
Takeda to Present Results from Phase 3 ALTA-1L Trial Highlighting Intracranial Efficacy of ALUNBRIG® (brigatinib) Versus Crizotinib in First-Line Advanced ALK+ Non-Small Cell Lung Cancer19.10.2018 12:00 | Pressemelding
Takeda Pharmaceutical Company Limited (TSE: 4502) today announced that intracranial efficacy data from the Phase 3 ALTA-1L (ALK in Lung Cancer Trial of BrigAtinib in 1 st Line) trial showed improved intracranial progression-free survival (PFS) and intracranial objective response rate (ORR) with ALUNBRIG (brigatinib) compared to crizotinib among anaplastic lymphoma kinase-positive (ALK+) non-small cell lung cancer (NSCLC) patients. Data for these secondary endpoints will be presented in a poster discussion at the European Society for Medical Oncology (ESMO) 2018 Congress on Friday, October 19 at 2:00 p.m. CET in Munich, Germany. These results further support ALUNBRIG as a potential treatment for adults with ALK+ locally advanced or metastatic NSCLC who had not received a prior ALK inhibitor. ALUNBRIG is currently not approved as first-line therapy for advanced ALK+ NSCLC. “ALK+ NSCLC often spreads to the brain, so having options that can clearly demonstrate efficacy both in the brain an